HOOKIPA Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Malte Peters

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	16.88%
CEO görev süresi	1.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Dec 21

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

Unfortunately for some shareholders, the HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) share price has dived 26% in the last...

Analiz Makalesi • Nov 19

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Sep 27

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shareholders that were waiting for something to happen have been dealt a blow with...

Analiz Makalesi • Aug 13

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

To the annoyance of some shareholders, HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares are down a considerable 29% in the...

Analiz Makalesi • Jun 22

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares have had a horrible month, losing 34% after a relatively good period...

Analiz Makalesi • Apr 28

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shares have continued their recent momentum with a 25% gain in the last month...

Analiz Makalesi • Mar 24

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

The analysts covering HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) delivered a dose of negativity to shareholders today, by...

Analiz Makalesi • Aug 11

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...

Analiz Makalesi • May 16

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

One thing we could say about the analysts on HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) - they aren't optimistic, having just...

Analiz Makalesi • Apr 26

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analiz Makalesi • Nov 19

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Shareholders in HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) may be thrilled to learn that the analysts have just delivered a...

Seeking Alpha • Jul 25

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Clinical-stage biotech HOOKIPA Pharma (NASDAQ:HOOK) announced on Monday that the FDA accepted its Investigational New Drug (IND) application for HB-300, an experimental therapy for metastatic castration-resistant prostate cancer. A Phase 1/2 trial for the treatment is expected to start by early next year. “FDA acceptance of our IND application for HB-300 is a key milestone as we expand and diversify our oncology pipeline and arenavirus platform from viral antigens to self-antigens,” Chief Executive Joern Aldag remarked. HB-300 is identified as an arenaviral immunotherapy designed to target two well-established antigens of prostate cancer, PAP and PSA. Parallelly, HOOKIPA (HOOK) announced that the FDA accepted the Drug Master File (DMF) to support the future submission of data specific to its replicating arenavirus platform. With the concurrent acceptance of DMF, “we have reduced cycle time between completion of preclinical studies and clinical entry of our pipeline projects,” Aldag added. Read: In April, HOOKIPA (HOOK) announced pre-clinical data supporting the potential of its arenaviral platform against various cancers.

CEO Tazminat Analizi

Malte Peters'un ücretlendirmesi HOOKIPA Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2025	n/a	n/a	-US$73m
Dec 31 2024	US$2m	US$281k	-US$44m
Sep 30 2024	n/a	n/a	-US$43m
Jun 30 2024	n/a	n/a	-US$49m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$232k	n/a	-US$82m

Tazminat ve Piyasa: Malte 'nin toplam tazminatı ($USD 1.67M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.77K ).

Tazminat ve Kazançlar: Malte şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Malte Peters (63 yo)

1.8yrs

Görev süresi

US$1,666,767

Tazminat

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Malte Peters	CEO, President & Director	1.8yrs	US$1.67m	Veri yok
Mary Coelho	Executive VP	1.8yrs	US$1.08m	0.17% $ 25.4k
Daniel Pinschewer	Co-Founder & Member of Scientific Advisory Board	15.3yrs	Veri yok	Veri yok
Mark Winderlich	Chief Research & Development Officer	2.1yrs	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: HOOK 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Malte Peters	CEO, President & Director	3.3yrs	US$1.67m	Veri yok
Mary Coelho	Executive VP	3.1yrs	US$1.08m	0.17% $ 25.4k
Daniel Pinschewer	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Paul-Henri Lambert	Member of Scientific Advisory Board	no data	US$46.34k	Veri yok
Sean Cassidy	Independent Director	1.8yrs	US$79.53k	0% $ 0
Igor Matushansky	Chairman of the Scientific Advisory Board	no data	US$1.42m	Veri yok
Julie O'Neill	Independent Non-Executive Chair	7.5yrs	US$89.99k	0.0039% $ 590.8
David Kaufman	Independent Director	7.1yrs	US$81.32k	0.0036% $ 543.3

3.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HOOK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/17 07:28
Gün Sonu Hisse Fiyatı	2026/05/15 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

HOOKIPA Pharma Inc. 5 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alec Stranahan	BofA Global Research
Swayampakula Ramakanth	H.C. Wainwright & Co.
Debjit Chattopadhyay	H.C. Wainwright & Co.

HOOKIPA Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

HOOKIPA Pharma Inc. Announces Board Changes

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Recent updates

HOOKIPA Pharma Inc. Files Form 15

HOOKIPA Pharma Inc.(NasdaqCM:HOOK) dropped from NASDAQ Composite Index

Consensus revenue estimates decrease by 10%

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Poolbeg Pharma PLC (AIM:POLB) cancelled the acquisition of HOOKIPA Pharma Inc. (NasdaqCM:HOOK) in a reverse merger transaction.

New minor risk - Share price stability

Poolbeg Pharma PLC (AIM:POLB) entered into non-binding discussions to acquire HOOKIPA Pharma Inc. (NasdaqCM:HOOK) for $1.3 million in a reverse merger transaction.

Consensus EPS estimates fall by 57%

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

New major risk - Revenue and earnings growth

Price target decreased by 11% to US$38.75

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Doses First Patients with Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

Price target increased by 16% to US$43.50

Less than half of directors are independent

HOOKIPA Pharma Inc. Announces Board Changes

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Second quarter 2024 earnings: Revenues miss analyst expectations

HOOKIPA Pharma Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Consensus estimates of losses per share improve by 18%

Price target increased by 8.7% to US$50.00

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting

First quarter 2024 earnings released: EPS: US$0.11 (vs US$0.27 loss in 1Q 2023)

HOOKIPA Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

HOOKIPA Pharma Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

HOOKIPA Pharma Provides Non-Compliance Update

Price target decreased by 11% to US$4.17

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Consensus revenue estimates increase by 14%

Price target decreased by 7.6% to US$4.32

HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023

HOOKIPA Pharma Inc. to Report Q3, 2023 Results on Nov 09, 2023

Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024

HOOKIPA Pharma Inc. Announces Management Changes

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

Price target increased by 16% to US$5.38

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

HOOKIPA Pharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates upgraded to US$1.09 loss

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

HOOKIPA Pharma Inc. to Report Q1, 2023 Results on May 11, 2023

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Less than half of directors are independent

Price target decreased by 18% to US$4.64

Full year 2022 earnings: EPS and revenues exceed analyst expectations

HOOKIPA Pharma Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Appoints Katia Schlienger as Chief Medical Officer and Malte Peters to Board of Directors